Evaluating the effectiveness and safety of rosemary (Rosmarinus officinalis L.) on cognitive impairments, and positive and negative symptoms in patients with chronic schizophrenia: double blind placebo-controlled randomized trial
Not Applicable
Recruiting
- Conditions
- Chronic schizophrenia.Schizophrenia
- Registration Number
- IRCT20110310006026N13
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Hospitalized patients with chronic schizophrenia (6 months or more should be passed from illness commencement) based on DSM-V criteria
Having no significant change in medication or symptoms over the previous 2 months
Exclusion Criteria
Mental retardation
Substance dependence
History of significant medical illness
Alterations in the received medications
Hypersensitivity reactions to rosemary
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive functions. Timepoint: At baseline and 4 weeks after intervention. Method of measurement: Screen for Cognitive Impairment in Psychiatry (SCIP) questionnaire.;Positive and negative symptoms. Timepoint: At baseline and 4 weeks after intervention. Method of measurement: Positive and Negative Syndrome Scale (PANSS) questionnaire.
- Secondary Outcome Measures
Name Time Method